基于临床和内镜评估的pH依赖型美沙拉嗪控释制剂治疗溃疡性结肠炎的疗效：一项回顾性队列研究
Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study.
作者信息
Matsumoto Satohiro, Yoshida Yukio
机构信息
Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
出版信息
Clin Exp Gastroenterol. 2015 Jul 31;8:225-30. doi: 10.2147/CEG.S86528. eCollection 2015.
BACKGROUND
We conducted a retrospective cohort study to clinically and endoscopically assess the efficacy of delayed-release mesalazine for ulcerative colitis.
METHODS
The study included 104 ulcerative colitis patients (52 men, 52 women) initiated on treatment with delayed-release mesalazine between 2009 and 2012. The clinical symptoms at months 0, 1, and 12 were scored using the clinical activity index. An endoscopic index was also used to determine disease activity in 72 patients who underwent total colonoscopy before and after mesalazine treatment.
RESULTS
The clinical activity index at months 0, 1, and 12 were 4.6±2.8, 3.4±1.8, and 2.8±1.4, respectively, decreasing with time after the start of mesalazine treatment (P<0.001). The endoscopic index decreased significantly from 4.5±3.2 before to 3.1±2.8 after the start of delayed-release mesalazine treatment in the mean follow-up period of 1.0±0.4 years (P<0.001).
CONCLUSION
Delayed-release mesalazine was confirmed to be effective both clinically and endoscopically.
背景
我们进行了一项回顾性队列研究，以临床和内镜方式评估缓释美沙拉嗪治疗溃疡性结肠炎的疗效。
方法
该研究纳入了2009年至2012年间开始接受缓释美沙拉嗪治疗的104例溃疡性结肠炎患者（男52例，女52例）。使用临床活动指数对第0、1和12个月时的临床症状进行评分。还采用内镜指数对72例在美沙拉嗪治疗前后接受全结肠镜检查的患者的疾病活动度进行测定。
结果
第0、1和12个月时的临床活动指数分别为4.6±2.8、3.4±1.8和2.8±1.4，在开始使用美沙拉嗪治疗后随时间下降（P<0.001）。在平均随访1.0±0.4年期间，内镜指数从缓释美沙拉嗪治疗开始前的4.5±3.2显著降至治疗后的3.1±2.8（P<0.001）。
结论
证实缓释美沙拉嗪在临床和内镜方面均有效。
Zotero 插件